Skip to content

Steroid-dependent ulcerative colitis pathogenesis of complex multi-center alternative medicine therapy, randomized, controlled clinical study

Steroid-dependent ulcerative colitis pathogenesis of complex multi-center alternative medicine therapy, randomized, controlled clinical study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15005760
Enrollment
Unknown
Registered
2015-01-02
Start date
2015-01-12
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

TCM Group:Oral Chinese medicine Qinchang Lianyang Granule + Guanchang Fang granule
Control:Azathioprine

Sponsors

Affiliated Hospital of Nanjing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Steroid-dependent patients with ulcerative colitis; 2. The TCM differentiation is spleen kidney deficiency, damp-heat syndrome; 3. Male and female,age between 18-65; 4. Informed consent is signed.

Exclusion criteria

Exclusion criteria: 1. Subject with bacillary dysentery, Amoebic dysentery, Chronic schistosomiasis, Tuberculosis of the intestines and Crohn's disease, Ischemic colitis, Radiation enteritis; 2. Subject with serious complications such as Local stenosis, Intestinal obstruction, Intestinal perforation, Toxic colon dilatation, Bleeding, Colon Cancer, Colorectal cancer; 3. Woman who is pregnant or try to conceive. Woman who is breast-feeding baby; 4. Subjects with severe primary disease of heart, and lung diseases affect living; ALT Above the twice upper limit of normal; Cr Above the upper limit of normal; PLT less than 50*10^9/L; WBC less than 3.0*10^9/L; 5. Patients with disabilities in law; 6. Suspected or indeed alcohol, drug abuse history; 7. According to judgment of the investigator, having other diseases which may reduce the likelihood of participation or complex the participation; 8. Subject who is allergic, such as who is allergic to two or more medications or knowned medications; 9. Subject who is included in other clinical trials.

Design outcomes

Secondary

MeasureTime frame
endoscopic response rate;endoscopic remission rate;TCM clinical syndrome efficacy;Laboratory tests;Recurrence rate;

Primary

MeasureTime frame
Clinical efficient rate;Reduction time and withdraw time of steroid;Clinical remission rate;

Countries

China

Contacts

Public ContactHong Shen
shenhong999@163.com+86 13851872859

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026